Form 4: Neurocrine Biosciences Director Stephen A. Sherwin Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Director Stephen A. Sherwin reported the acquisition of 2,869 Restricted Stock Units (RSUs) of Neurocrine Biosciences Inc. on May 22, 2024, which will vest on May 22, 2025.
Summary
- Stephen A. Sherwin, a director of Neurocrine Biosciences Inc., filed a Form 4 on May 23, 2024, reporting a transaction.
- On May 22, 2024, Sherwin acquired 2,869 Restricted Stock Units (RSUs).
- Each RSU represents the right to receive one share of Neurocrine Biosciences' common stock upon vesting.
- The RSUs will vest in full on May 22, 2025.
- Following the reported transaction, Sherwin directly owns 2,869 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock options, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock-based compensation to a company director, which is a common practice in publicly traded companies to align the interests of management with those of shareholders.
Stakeholder Impact
- The granting of RSUs aligns the director's interests with those of shareholders, incentivizing them to work towards increasing the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/22/2024 | Date of transaction: Stephen A. Sherwin acquired 2,869 Restricted Stock Units. |
| 05/22/2025 | Vesting date for the 2,869 Restricted Stock Units. |
| 05/23/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.